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Abstract: Capecitabine (Xeloda®, Roche, Basel, Switzerland) is a pro-drug of 5-fluorouracil 
(5-FU), and it is converted to 5-FU in the cancer cell by enzymatic degradation. The role of 
capecitabine in colorectal cancer has evolved in the last 15 years. In early trials in the metastatic 
setting, capecitabine has shown superior response rates compared with those achieved with 5-FU 
(Mayo Clinic regimen) (26% vs 17%), with equivalent progression-free survival and overall 
survival. In the adjuvant setting, the Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial 
demonstrated that capecitabine as a single agent led to improvement in relapse-free survival 
(hazard ratio: 0.86, 95% confidence interval: 0.74–0.99, P = 0.04) and was associated with 
significantly fewer adverse events than 5-FU plus leucovorin (LV , folinic acid). On the basis 
of the X-ACT trial, capecitabine was approved by the United States Food and Drug Adminis-
tration, the National Institute for Clinical Excellence, and the Scottish Medicines Consortium 
as monotherapy for the adjuvant treatment of stage III colon cancer. The next step was to 
incorporate capecitabine into combination therapy. The XELOXA trial studied the combination 
of capecitabine and oxaliplatin (XELOX) vs 5-FU/LV and demonstrated 5-year disease-free 
survival of 66% for XELOX, compared with 60% for 5-FU/LV . The toxicity profile was also 
quite comparable in the two arms. So both the single agent use of capecitabine as well as in 
combination with oxaliplatin can be considered as part of the standard of care in management 
of early colon cancer in appropriately selected patient groups.
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Colon cancer
Colon cancer is the second most common cancer in Europe and the third most com-
mon in UK.1–3 The incidence of colon cancer has not changed a lot in recent time, but 
age-standardized mortality has improved in the last 30 years.3 This improvement is 
more pronounced in early colon cancer, where management usually consists of surgery 
followed by adjuvant treatment.4 Adjuvant treatment is fluoropyrimidine based, and it 
has now become a standard of care in the management of colon cancer.
Prognostic/predictive markers to define adjuvant 
treatment of colon cancer
The most important prognostic factors at primary diagnoses are TNM (tumor, nodes, 
and metastases) staging of disease and the ability to perform complete resection of all 
macroscopic disease. After surgery, the next question always is the need for adjuvant 
treatment and also the choice of chemotherapeutic agent. The goal of postoperative Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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(adjuvant) therapy is to eradicate occult micrometastases 
present at time of surgery thereby increasing the cure rate. 
Poor prognosis is associated with lymphovascular space inva-
sion, perineural invasion, perforation/ulceration of tumor, 
signet ring/mucinous histology, and number of lymph nodes 
involved.5–7 Evidence at the moment favors use of adjuvant 
treatment in stage III colon cancer (lymph node positive dis-
ease). However, with stage II colon cancer, adjuvant treatment 
is a question of debate, as data only show modest 3% 5-year 
survival benefit with adjuvant chemotherapy compared with 
observation alone.8
Many molecular markers have been speculated to affect 
outcome, and examples are microsatellite instability (MSI-H), 
tumor-DNA ploidy, chromosomal deletions, and mutated p53. 
The influence of microsatellite instability to predict response 
to adjuvant 5-fluorouracil (5-FU)-based chemotherapy is con-
troversial, and so far the evidence is retrospective and conflict-
ing, with some studies showing no effect on overall survival 
but others showing a trend toward lower or improved survival. 
Ribic et al demonstrated survival advantage with adjuvant 
chemotherapy in microsatellite stable colon cancer and no 
benefit for patients with microsatellite instability positive 
tumor.28 In contrast to above, Kim et al found no relationship 
between MSI and chemotherapy in terms of overall survival.29 
Similarly, allelic loss on chromosome 18q and p53 mutation 
are also considered as poor prognostic signs, but incorporation 
of these molecular markers into clinical evidence is difficult 
at present on grounds of lack of robust evidence.
History of adjuvant treatment  
with evolution of 5-FU
Colon cancer was considered to be refractory to any cytotoxic 
treatment until 5-FU was designed, synthesized, and patented 
by Charles Heidelberger in 1957.9 5-FU is a pyrimidine 
antagonist, and it functions to inhibit DNA synthesis by 
blocking the formation of normal pyrimidine nucleotides 
via thymidylate synthase inhibition.
Fluorouracil has been the established treatment for 
locally advanced and metastatic colorectal cancer for nearly 
four decades. Meta-analysis in the early 1990s showed that 
single-agent 5-FU has a reasonable efficacy in patients with 
metastatic colon cancer, providing a tumor response rate of 
10%–15%. The addition and modulation of fluorouracil by 
leucovorin (LV , folinic acid) lead to doubling of the response 
rate.10 Moving from metastatic settings to adjuvant, the study 
by Moertel et al11 was the first breakthrough trial which showed 
survival advantage in patients with stage III colon cancer with 
fluorouracil plus levamisole. It demonstrated a reduction in the 
recurrence rate by 40% (P , 0.0001) and the death rate by 33% 
(P = 0.0007). In the same trial, levamisole on its own reduced 
the recurrence rate by only 2% and the death rate by only 6%.11 
Also, a meta-analysis in 1988 showed similar results, with a 
small survival benefit for patients receiving adjuvant 5-FU 
after surgery compared with surgery alone (odds ratio of death: 
0.83, 95% confidence interval: 0.70–0.98).10
In the same era, efforts were made to increase the antine-
oplastic activity of fluorouracil by adding a cytostatic agent 
which can modulate its mechanism of action. LV was the first 
success story, and IMPACT (The International Multicenter 
Pooled Analysis of Colon Cancer Trials), a meta-analysis, 
showed that treatment with 5-FU/LV after surgery was 
associated with a 22% reduction in death rate compared with 
surgery alone in stage III colon cancer.10,12
As treatment of colon cancer evolved more, research ques-
tions were raised about the method of infusion (continuous 
infusion vs bolus infusion) of 5-FU along with dosage of LV . 
Pan-European Trials in Adjuvant Colon Cancer (PETACC-2 
Trial) had examined the above question and failed to show any 
difference in outcome between continuous infusional regimens 
(Mayo regimen) vs Bolus infusion regimen. However the toxic-
ity profile favored the infusional regimen with lesser incidence 
of grade III/IV diarrhea, neutropenia, and mucositis.13 Similarly, 
trials did not show any survival benefit of high dose LV com-
pared with low dose LV in combination with 5-FU.8
At the same time, oxaliplatin and irinotecan were showing 
activity and potential roles in management of colon cancer. 
Oxaliplatin shows synergy to 5-FU by downregulation of thy-
midylate synthase, and its role was established in Multicenter 
International Study of Oxaliplatin/Fluorouracil/Leucovorin in 
the Adjuvant Treatment of Colon Cancer (MOSAIC), where 
2246 patients with stage II (40%) or stage III (60%) colon 
cancer were randomized to receive 6 months of infusional 
fluorouracil and LV with or without oxaliplatin.14–16 After a 
median follow-up of 49 months, the 4-year disease-free sur-
vival was statistically superior in those patients who received 
oxaliplatin and 5-FU/LV , compared with those who received 
5-FU/LV (72.9% vs 68.3%) (see Table 1 and Figure 1).
In contrast to the promising infusional 5-FU/oxaliplatin 
regimen, an irinotecan/bolus 5-FU combination never lived 
up to the expectations in adjuvant settings. The PETACC-3 
Trial was a randomized Phase III trial which compared use of 
biweekly infusional fluorouracil/LV alone or in combination 
with irinotecan in the adjuvant treatment of stage III colon 
cancer. A total of 3278 patients (945 with stage II disease; 
2333 with stage III disease) were randomized to receive 
fortnightly infusional 5-FU/LV alone or with the addition of Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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irinotecan. At a median follow-up of 32 months, the 3-year 
disease-free survival was 62.9% for the irinotecan combina-
tion and 59.9% for those receiving 5-FU/LV , a difference 
which was not statistically significant (hazard ratio: 0.89 
[95% confidence intervals: 0.77–1.03], P = 0.107).30
Capecitabine: pro-drug of 5-FU
An oral preparation of 5-FU would have obvious benefits in 
terms of convenience for patients. Unfortunately, 5-FU is not 
suitable for oral administration because of variable bioavail-
ability and unpredictable degradation in the gastrointestinal 
tract. Inter- and intra-individual variation in dihydropyrimi-
dine dehydrogenase activity (the main catabolic enzyme for 
5-FU), particularly in gastric mucosa, was also a reason for 
unsuitability of oral 5-FU.17 Capecitabine (Xeloda®, Roche, 
Basel, Switzerland) was designed as a pro-drug of fluorouracil, 
which will deliver 5-FU selectively to the tumor minimizing 
systemic toxicities. After   gastrointestinal absorption, capecit-
abine is hydrolyzed in the liver by carboxyl esterase to produce 
5′-deoxy-5-fluorocytidine, and this moiety is then deaminated 
on its pyrimidine ring to produce 5′-deoxy-5-fluorouridine   
by cytidine deaminase, an enzyme located principally in 
hepatic and neoplastic tissue. The last enzymatic step of con-
version of 5′-deoxy-5-fluorouridine to 5-FU in the cancer 
cell is catalyzed by thymidine phosphorylase, thus minimiz-
ing systemic exposure to 5-FU. Thymidine phosphorylase 
occurs at higher levels in most solid tumors than in the 
corresponding normal tissue. Human pharmacokinetic stud-
ies have demonstrated that capecitabine is well absorbed 
and rapidly converted to noncytotoxic intermediates and 
that intra-tumoral concentrations of 5-FU are significantly 
higher than plasma and normal tissue levels.18–20 Again, 
capecitabine completed the same cycle as was done with 
5-FU, and it was tested in metastatic settings first where 
it showed good equivalent efficacy and better tolerability 
compared with 5-FU, and subsequently also in the adjuvant 
setting.
In early trials in the metastatic setting, capecitabine demon-
strated response rate superior to those achieved with the Mayo 
Clinic regimen of 5-FU/LV (26% vs 17%), with equivalent pro-
gression-free survival and overall survival.21,22 Capecitabine was 
also better tolerated than 5-FU/LV , and its administration was 
associated with a reduced consumption of medical resources.27 
As a result, capecitabine was considered as a good first-line treat-
ment for metastatic colorectal cancer and became an established 
alternative to the combination of fluorouracil and LV .
The next challenge was to establish the role of capecitabine 
in adjuvant settings in colon cancer. The Xeloda in Adjuvant 
Chemotherapy Trial (X-ACT) investigated the efficacy and 
safety of capecitabine treatment vs 5-FU/LV treatment (Mayo 
Clinic regimen) in the postoperative adjuvant setting in 1987 
patients with stage III (Dukes’ C) colon cancer. This trial 
demonstrated that capecitabine was at least as effective as 
bolus 5-FU/LV in terms of disease-free and overall survival, 
with trends towards superiority for both. Moreover, there 
was less toxicity associated with capecitabine, apart from 
hand–foot syndrome, which was significantly more prevalent 
(Figures 2 and 3). On the basis of the X-ACT trial, capecit-
abine was approved by the United States Food and Drug 
Administration, the National Institute for Clinical Excellence, 
Table 1 MOSAiC trial results
Median follow-up,  
months
Disease-free survival, % Reduction in risk  
of recurrence, %
Overall survival, %a
FOLFOX4  
(n = 1123)
5-FU/LV  
(n = 1123)
P-value FOLFOX4  
(n = 1123)
5-FU/LV  
(n = 1123)
37.9 78.2 72.9 23 0.002 84 81.9
48.6 75.9 69.1 24 0.0008 79.2 76.6
56.2 76.4 69.8 23 ,0.001 80.2 77
Abbreviations: 5-FU, 5-fluorouracil; FOLFOX, combination of folinic acid (leucovorin), 5-fluorouracil, and oxaliplatin; LV, leucovorin; MOSAIC, multicenter international 
study of oxaliplatin/fluorouracil/leucovorin in the adjuvant treatment of colon cancer.
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
06 12
Stage II
Stage III
1.00 (0.71–1.42)
HR (95% Cl)
0.80 (0.66–0.98)
LV5FU2 stage II
FOLFOX4 stage II
P = 0.029
4.4%
0.1%
P = 0.996
FOLFOX4 stage III
LV5FU2 stage III
18 24 30 36 42 48 54
Overall survival (months)
P
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
60 66 72 78 84 90 96
Figure  1  Overall  survival  in  stage  II  vs  stage  III  patients  (4-year  follow-up  in 
MOSAIC trial).
Abbreviations: 5FU, 5-fluorouracil; CI, confidence interval; FOLFOX, combination 
of folinic acid (leucovorin), 5-fluorouracil, and oxaliplatin; HR, hazard ratio; LV, 
leucovorin;  MOSAIC,  multicenter  international  study  of  oxaliplatin/fluorouracil/
leucovorin in the adjuvant treatment of colon cancer.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
298
Hameed and Cassidy
0.0
0.2
0.4
0.6
0.8
1.0
06 12 18 24 30 36 42 48 54
Time (months)
Test of noninferiority P = 0.000116
Test of superiority P = 0.06 
E
s
t
i
m
a
t
e
d
 
p
r
o
b
a
b
i
l
i
t
y
60
Capecitabine (n = 1004)
5-FU/LV (n = 983)
71.4%
5-year
68.4%
66 72 78 84 90 96
ITT population
Figure 2 Overall survival curve (X-ACT trial).
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Figure 4 Incidence of grade III/IV toxicities in XELOXA trial.
Abbreviations:  5-FU,  5-fluorouracil;  LV,  leucovorin;  XELOX,  combination  of 
capecitabine and oxaliplatin.
and the Scottish Medicines Consortium as monotherapy for 
the adjuvant treatment of stage III colon cancer.
The next question was: does oxaliplatin also show synergy 
with capecitabine in a similar way as with 5-FU (MOSAIC 
trial). The XELOXA NO16968 trial answered the question. 
It recruited 1886 patients with stage III colon cancer at 
226 study sites across 29 countries. They were randomly allo-
cated to treatment with XELOX (oxaliplatin/capecitabine) or 
5-FU/LV . This trial showed 5-year disease-free survival was 
66% for XELOX vs 60% for 5-FU/LV . The incidence of grade 
3/4 toxicities in the 5-FU/LV arm (n = 924) and XELOX arm 
(n = 937) were comparable   (Figure 4).23
Unfortunately, so far none of the “targeted” agents have 
shown efficacy in the adjuvant setting in colon cancer. A 
North Central Cancer Treatment Group randomized Phase III 
trial investigated the addition of cetuximab to mFOLFOX6 
(modified LV , 5-FU, and oxaliplatin), and it showed no benefit 
for patients with resected stage III wild-type KRAS colon 
cancer.24 Recent trials with bevacizumab in combination with 
XELOX have failed to show any improvement in disease-free 
survival and overall survival in adjuvant therapy of colon 
cancer.25,26
Conclusion
In conclusion, both the single agent use of capecitabine as 
well as in combination with oxaliplatin can be considered 
as part of the standard of care in management of early colon 
cancer in appropriately selected patient groups. Any role Cancer Management and Research
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of targeted treatments in combination with capecitabine 
is a research question, and such an approach cannot be 
recommended outside the context of clinical trials. We also 
have to wait for robust data regarding predictive/prognostic 
molecular markers in colon cancer and their role in defining 
need and choice of adjuvant treatment in colon cancer.
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